MEANS AND METHOD FOR TREATING AND/OR PREVENTING NECROTIZING ENTEROCOLITIS
Compositions comprising a source of alkaline phosphatase that prevent or reduce toxic influx of lipopolysaccharide (LPS) through mucosal layers of a mamalian body cavity and methods of using these compositions for those purposes are disclosed. Such a source of alkaline phosphatase, preferably in a medical food such as infant milk formula, is eaten, drunk or otherwise administered for prophylaxis or treatment of LPS-mediated or LPS-exacerbated disease.
1 . A medical food comprising enzymatically active alkaline phosphatase (AP) or an enzymatically active part thereof.
2 . The medical food according to claim 1 , wherein said medical food is an infant formula or (human) milk fortifier.
3 . The medical food according to claim 1 , designed to treat necrotizing enterocolitis.
4 . The medical food according to claim 1 , wherein the medical food comprises dry powder milk, a dry powder hydrolysate of milk, and/or dry powder soy protein.
5 . The medical food according to claim 1 , wherein the AP is a mammalian intestinal AP, a tissue non specific AP, a placental AP or a liver AP.
6 . The medical food according to claim 1 , wherein the AP is a recombinant or a modified recombinant AP.
7 . The medical food according to claim 1 wherein the AP is of human or bovine origin.
8 . The medical food according to claim 1 wherein the AP is enteric coated for oral administration and delivery to the gastro-intestinal tract mucosa.
9 . The infant formula according to claim 2 , comprising between 0.05 and 50,000 IU AP/g of dry powder and/or comprising between 0.8 and 800,000 IU AP/liter of liquid formula.
10 . The fortifier according to claim 2 , comprising between 0.2 and 200,000 IU AP/g of dry powder and/or comprising between 3 and 3,000,000 IU AP/liter of liquid fortifier.
11 . A method for preventing and/or reducing necrotizing enterocolitis in a subject, comprising administering to the mucosal layer of the gastrointestinal tract of said subject an enzymatically active alkaline phosphatase.
12 . The method according to claim 11 wherein the AP is administered orally.
13 . The method according to claim 11 , wherein the AP is administered via a suppository.
14 . The method according to claim 11 , wherein the AP is administered via a gastric tube, a transpyloric tube, and/or a rectal tube.
15 . The method according to claim 11 , wherein the AP is administered at least once per day.
16 . The method according to claim 11 , wherein the enzymatically active AP is present in a medical food according to claim 1 .
17 . A method for manufacturing an infant formula or milk fortifier for use in preventing and/or reducing inflammation of the gastro-intestinal tract mucosa, the method comprising the steps of adding a suitable amount of enzymatically active AP to a dry powder infant formula, a dry powder (human) milk fortifier, a liquid infant formula, a liquid (human) milk fortifier, and/or human milk.